This study identifies VISTA (V-domain Ig suppressor of T cell activation) as a ligand for PSGL-1 (P-selectin glycoprotein ligand-1) that binds selectively under acidic pH conditions, such as those found in tumor microenvironments. The interaction between VISTA and PSGL-1 suppresses T cell activation. Blocking this interaction with pH-selective antibodies reverses immune suppression and enhances anti-tumor responses in vivo.
VISTA binds to PSGL-1 under acidic conditions, leading to T cell suppression; blocking this interaction enhances anti-tumor immunity.
Human VISTA Knockin mouse model developed by genOway, expressing human VISTA to evaluate the efficacy of VISTA-targeting antibodies in an immunocompetent setting.
Cancer immunotherapy, Immune checkpoint, VISTA, PSGL-1, Tumor microenvironment
Humanized Knockin model, VISTA gene replacement, pH-selective antibody evaluation
From model design to experimental results
Featured in 600+ scientific articles
Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions
Generated with biopharma partners and in-house
and guaranteed freedom to operate
Models with certified health status from professional breeders in US and Europe
